Daily Change in COVID-19 Cases, US
January 22, 2020 – February 27, 2021

TOTAL Cases Reported Since 1/22/20
28,355,420

NEW Cases Reported to CDC on 2/27/21
69,876

Change in 7-Day Case Average
+2.1%

Current 7-Day Case Average (2/21/21 - 2/27/21)
67,176

Prior 7-Day Case Average (2/14/21 - 2/20/21)
65,812

Reported 7-day moving average of COVID-19 cases has decreased 73% since January 11, 2021
New Admissions of Patients with Confirmed COVID-19
August 1, 2020 – February 26, 2021

Patients Currently Hospitalized with COVID on 2/26/21
39,973

New Admissions on 2/26/21
5,222

Peak in New Admissions (1/5/21)
18,006

Change in 7-Day Average of New Admissions
-10.0%

Current 7-Day Average of New Admissions (2/20/21 - 2/26/21)
6,015

Prior 7-Day Average of New Admissions (2/13/21 - 2/19/21)
6,687

Reported 7-day moving average of hospitalizations has decreased 64% since January 9, 2021
Daily Change in COVID-19 Deaths, United States
January 22, 2020 – February 27, 2021

TOTAL Deaths Reported Since 1/22/2020
510,777

NEW Deaths Reported to CDC on 2/27/21
1,828

Change in 7-Day Death Average
+2.4%

Current 7-Day Death Average (2/21/21 - 2/27/21)
1,962

Prior 7-Day Death Average (2/14/21 - 2/20/21)
1,917

Forecasted Total Deaths by 3/20/21
526,000-548,000
FDA Issues Emergency Use Authorization for Third COVID-19 Vaccine

Janssen COVID-19 Vaccine
Janssen COVID-19 Vaccine: Phase 3 COV3001 (ENSEMBLE) Study

- **66% vaccine efficacy against moderate to severe/critical COVID-19 across all countries**
  - Protection as of 2 weeks after vaccination

- **72% vaccine efficacy against moderate to severe/critical COVID-19 in the United States**
  - Participants reflected diversity of US population (n > 19,000)

- **85% vaccine efficacy against severe COVID-19 globally, including the United States**
  - Consistent vaccine efficacy against severe disease across all regions
  - Equally high protection in South Africa (n > 6,500) where B.1.351 is highly prevalent (> 95%)
  - Complete protection against COVID-19 related hospitalizations and deaths
Janssen COVID-19 Vaccine Protective Against Emerging SARS-CoV-2 Variants

Trial conducted in areas where COVID-19 incidence was highest and where variants were emerging

United States
86% VE severe/critical
96% D614G
3% CAL.20C

Brazil
88% VE severe/critical
69% P.2 lineage
31% D614G

South Africa
82% VE severe/critical
95% B.1.351 lineage
3% D614G
mRNA Vaccine Approach

mRNA for spike protein of coronavirus → Inject into muscle cells → Muscle cells read the mRNA and make spike protein
Janssen COVID-19 Vaccine Approach

Adenovirus (Ad26) Expressing SARS-CoV-2 Spike Protein

Intramuscular injection

SARS-CoV-2 spike insert

Adenovirus DNA

Human cell

DNA

RNA

Spike protein
## Selected COVID-19 Vaccines

<table>
<thead>
<tr>
<th>Platform</th>
<th>Developer</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nucleic Acid (mRNA)</td>
<td><strong>moderna</strong></td>
<td>94% efficacy vs. symptomatic disease → EUA</td>
</tr>
<tr>
<td></td>
<td><strong>BIONTECH</strong></td>
<td>95% efficacy vs. symptomatic disease → EUA</td>
</tr>
<tr>
<td>Adenovirus Vector</td>
<td><strong>Janssen</strong></td>
<td>72% efficacy in U.S. 85% efficacy overall vs. severe disease in U.S., South Africa, Latin America → EUA</td>
</tr>
<tr>
<td></td>
<td><strong>AstraZeneca</strong></td>
<td>63% efficacy vs. symptomatic disease in U.K., Brazil and South Africa → EUA TBD</td>
</tr>
<tr>
<td>Recombinant Protein and Adjuvant</td>
<td><strong>gsk SANOFI</strong></td>
<td>Phase 2 underway → Feb. 2021</td>
</tr>
<tr>
<td></td>
<td><strong>NOVAVAX</strong></td>
<td>89% efficacy vs. symptomatic disease in U.K. → EUA TBD</td>
</tr>
</tbody>
</table>
Role of NIH and the U.S. Government in the Development and Testing of the Johnson & Johnson (Janssen) COVID-19 Vaccine

- Decades of NIH support of basic, pre-clinical and clinical research to develop the adenovirus 26 (Ad26) vector
- Development of the stabilized pre-fusion spike protein by scientists at the NIAID Vaccine Research Center
- Utilization by J & J of the extensive domestic and international clinical trials network established by NIAID for HIV and Influenza
- Use of the NIAID-funded core laboratory of the HIV Vaccine Trials Network (HVTN) at the Fred Hutchinson Cancer Research Center to perform immunological testing
- Use of the Data and Safety Monitoring Board (DSMB) established by NIAID to monitor the trial
- Extensive Support by BARDA at APR of HHS to conduct the trial
- Pre-purchase of hundreds of millions of doses of vaccine by BARDA
The Vaccination Progress Report

7-day average daily doses administered by week as of 2/28/2021

Doses per day

<table>
<thead>
<tr>
<th>Week</th>
<th>Doses per day</th>
</tr>
</thead>
<tbody>
<tr>
<td>January 13-19</td>
<td>0.9 M/day</td>
</tr>
<tr>
<td>January 20-26</td>
<td>1.1 M/day</td>
</tr>
<tr>
<td>January 27-February 2</td>
<td>1.3 M/day</td>
</tr>
<tr>
<td>February 3-9</td>
<td>1.5 M/day</td>
</tr>
<tr>
<td>February 10-16</td>
<td>1.7 M/day</td>
</tr>
<tr>
<td>February 17-23</td>
<td>1.4 M/day</td>
</tr>
<tr>
<td>February 22-28</td>
<td>1.7 M/day</td>
</tr>
</tbody>
</table>